Burning Rock Biotech Ltd

Burning Rock Biotech develops and commercializes next-generation sequencing (NGS)-based cancer diagnostic tests for therapy selection and prognosis prediction. The company's test portfolio covers multiple cancer types including lung, gastrointestinal, breast, prostate, and ovarian cancers, utilizing both tissue and liquid biopsy samples. Primary products include OncoScreen Focus and OncoScreen Plus for tissue analysis, OncoCompass Plus and OncoCompass Target for liquid biopsy detection, and ColonCore for gastrointestinal cancer assessment. The company also offers CanCatch for minimal residual disease detection and OncoMaster, an automated NGS data analysis platform.

The business operates through three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company has established partnerships with major pharmaceutical companies including AstraZeneca, Bayer, Johnson & Johnson, and Merck KGaA for clinical trials and research collaborations. It also maintains a development and commercialization agreement with Myriad Genetics to license myChoice tumor testing in China.

Burning Rock Biotech operates across the People's Republic of China and the United States with 674 full-time employees. The company was founded in 2014 and is headquartered in Guangzhou, China. It is listed on Nasdaq with a market capitalization of approximately $0.3 billion.